US 12,168,678 B2
Heme sequesting peptides and uses therefor
Li Zhang, Plano, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on May 13, 2022, as Appl. No. 17/743,835.
Application 17/743,835 is a continuation of application No. 16/827,015, filed on Mar. 23, 2020, granted, now 11,358,991.
Claims priority of provisional application 62/821,823, filed on Mar. 21, 2019.
Prior Publication US 2022/0396601 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/16 (2006.01); A61K 45/06 (2006.01); A61P 31/10 (2006.01); A61P 35/00 (2006.01); C07K 14/24 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/24 (2013.01) [A61K 38/164 (2013.01); A61K 45/06 (2013.01); A61P 31/10 (2018.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01)] 27 Claims
 
1. A method of treating small cell carcinoma comprising administering to said subject a recombinant heme sequestering peptide (HeSP) comprising an amino acid substitution of Q32H in the Q32 loop of Yersinia pestis HasA.